Jiangsu Aidea Pharmaceutical Co., Ltd. ("Aidea Pharma"), set up in Year 2009, is located in Yangzhou, Jiangsu Province and listed on SSE STAR-Market on July 20, 2020.
Aidea Pharma focuses on critical medicine fields with anti-virus, anti-inflammatory and anti-tumor treatment, trying to serve the unmet clinical needs and is committed to exploring, researching and marketing innovative chemical medicines and human-sourced protein products.
In the early days of its establishment, Aidea Pharma successfully developed unique online human urine protein adsorption technology, using highly efficient resin to develop a set of effective process and achieve online and efficient adsorption of urinary proteins like Urinary Trypsin Inhibitor (UTI), Urokinase (UK), and Human Urinary Kallidinogenase (KN). Now Aidea Pharma becomes a large producer and supplier of human-sourced protein products in mainland China.
Since 2014, Aidea Pharma has begun to put more concern on developing innovative chemical products. In its current research pipeline, there are total 14 major products at different research stages, among which, 8 of them are national class I new drugsfor the treatment of HIV virus, cancer, inflammatory, etc.1 product has finished Phase III clinical study and applied New Drug Application, and 4 products have been approved to execute clinical study.
With the leadership of experienced senior experts and collaboration with high-level talents, Aidea Pharma has granted 36 patents and undertaken 3 projects of the 13th “Five-Year Plan” New Drug Research and Development National Major Scientific and Technological Special Projects administered by State Ministry of Science and Technology.
Aidea Pharma has been committed to becoming a respected and excellent pharmaceutical company in China.
| Full name | Jiangsu Aidea Pharmaceutical Co.,Ltd. |
|---|---|
| Abbreviations | AideaPharma |
| Code | 688488.SH |
| Founded | December 15, 2009 |
| Listing | July 20, 2020 |
| Domicile | Yangzhou, Jiangsu |
| Website | www.aidea.com.cn |
| ad@aidea.com.cn | |
| STAR Theme | Biomedicine |
| CSRC Sector | Manufacturing |
| Has weighted voting rights structure? | N/A |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 0.10 | 0.09 | - |
| R&D expenditure as a % of operating revenue | 15.71% | 16.50% | 22.35% |
| Operating Revenue | 289.06 | 345.23 | 276.91 |
| Net Income | 39.77 | 33.65 | 8.62 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 289.06 | 345.23 | 276.91 |
| Operating Costs | 144.26 | 197.30 | 166.31 |
| Operating Income | 49.55 | 35.20 | 8.22 |
| Pretax Income | 47.18 | 38.15 | 7.54 |
| Income Tax | 7.41 | 4.50 | -1.08 |
| Net Income | 39.77 | 33.65 | 8.62 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 1,006.72 | 368.11 | 310.36 |
| Non-current Assets-Total | 440.10 | 412.87 | 398.59 |
| Total Assets | 1,446.83 | 780.98 | 708.95 |
| Liabilities | |||
| Current Liabilities-Total | 73.00 | 209.13 | 175.11 |
| Non-current Liabilities-Total | 13.97 | 15.62 | 11.13 |
| Total Liabilities | 86.97 | 224.74 | 186.24 |
| Stockholder's Equity | |||
| Share Capital | 1,293.78 | 529.71 | 502.46 |
| Retained Profits | 66.08 | 26.53 | 20.26 |
| Total Owners' Equity | 1,359.86 | 556.24 | 522.71 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 56.17 | 56.20 | -33.50 |
| Net Cash Flows-Investing | -574.45 | -37.01 | -82.50 |
| Net Cash Flows-Financing | 626.70 | 23.45 | 37.80 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| 广州维美投资有限公司 | 94.50 | 22.50% |
| 维美投资(香港)有限公司 | 77.69 | 18.50% |
| 扬州乐凯企业管理合伙企业(有限合伙) | 23.63 | 5.63% |
| Starr International Investments HK V, Limited | 21.24 | 5.06% |
| AEGLE TECH LIMITED | 16.20 | 3.86% |
| AVIDIAN TECH LIMITED | 16.20 | 3.86% |
| 华泰紫金(江苏)股权投资基金(有限合伙) | 15.02 | 3.58% |
| 江苏毅达并购成长股权投资基金(有限合伙) | 14.56 | 3.47% |
| YYH Investment Holdings Limited | 13.50 | 3.21% |
| 傅和祥 | 13.17 | 3.13% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.